We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables.


 Twenty patients treated with meloxicam were followed up every 3 to 6 months.  Meloxicam administration was planned at 15 mg/day orally for 6 months.


 The cumulative probability of dropping out from our nonsurgical strategy using meloxicam was 35.0% at 1 year and 35.0% at 5 years.



meloxicam
We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables.


 Twenty patients treated with meloxicam were followed up every 3 to 6 months.  Meloxicam administration was planned at 15 mg/day orally for 6 months.


 The cumulative probability of dropping out from our nonsurgical strategy using meloxicam was 35.0% at 1 year and 35.0% at 5 years.



meloxicam
We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables.


 Twenty patients treated with meloxicam were followed up every 3 to 6 months.  Meloxicam administration was planned at 15 mg/day orally for 6 months.


 The cumulative probability of dropping out from our nonsurgical strategy using meloxicam was 35.0% at 1 year and 35.0% at 5 years.



meloxicam